Avingtrans plc Employee & PDMR Share Incentive Awards

Avingtrans plc

Avingtrans plc (LON:AVG), which designs, manufactures and supplies critical components, modules, systems and associated services to the energy, medical and industrial sectors, has announced that on 21 November 2023, the Board of Avingtrans, in accordance with the Company’s Share Option Plan, granted options over 606,000 ordinary shares of 5p each in the Company with an exercise price of 390.0 pence per Ordinary Share. The following Option Awards were granted to Directors:

DirectorNumber of Ordinary Shares subject to Option Awards
Steve McQuillan180,000
Stephen King160,000

Furthermore Austen Adams, Managing Director of the Group’s PSRE Division and a PDMR of the Company, has been granted Option Awards over a total of 110,000 Ordinary Shares.

The Option Awards may not be exercised until 3 years from the date of grant and are subject to a performance condition, being the increase in the Company’s adjusted EPS must be at least equal to the increase in RPI over the vesting period.

Avingtrans plc designs, manufactures and supplies original equipment, systems and associated aftermarket services to the energy, medical and industrial markets worldwide. 

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:

Latest Company News

Avingtrans subsidiary Adaptix gains FDA clearance for Ortho350

Avingtrans reported that its subsidiary Adaptix has received FDA 510(k) clearance for the Ortho350, a compact 3D orthopaedic imaging system designed for point of care use.

Avingtrans CEO on record revenue and strong order book momentum for FY25 (LON:AVG)

Avingtrans has delivered record revenue of £156.4 million for FY25, with Chief Executive Officer Steve McQuillan highlighting robust order book growth, major contract wins, and increasing demand across energy, defence, infrastructure and medical divisions.

Avingtrans appoints Stuart Gall as CEO of medical imaging division

Avingtrans Plc has announced the appointment of Stuart Gall as Divisional Chief Executive Officer of its medical imaging businesses, including Adaptix and Magnetica, effective on or before 10 March 2026.

Avingtrans Plc Record Results, New Nuclear Wins and the Power of AI-Driven Demand (Video)

Avingtrans CEO Steve McQuillan shares how AI, energy and infrastructure megatrends are driving record results — and why strategic deals could be back on the table in FY26.

Avingtrans reports record revenue and earnings growth in FY25

Avingtrans posted preliminary results for the year ended 31 May 2025, with revenue up 14.5% to a record £156.4m and adjusted EBITDA rising to £16.7m. Adjusted profit before tax increased 18% to £8.6m, while diluted EPS grew 28% to 23.7p.

Avingtrans secures $16m nuclear contracts with KHNP

Avingtrans’ US subsidiary, Hayward Tyler Inc., has won two contracts worth over $16m from Korea Hydro & Nuclear Power. The deals cover safety-related pumps and spare parts for nuclear reactors in South Korea, with manufacturing in Vermont and delivery scheduled by FY27.

    Search

    Search